Across TCGA pan-cancer cohorts, SEC1P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SEC1P data layer compared with 21 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher SEC1P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SEC1P expression acts as an unfavorable survival marker.
LIHC are the cancer types where SEC1P Mutation most reproducibly stratifies survival.